RESPONSE RATES IN ACUTE MYELOID LEUKEMIA WITH SUSPECTED GERMLINE DDX41 MUTATIONS

EHA Library, Jesus Gonzalez Lugo, 4160568

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): PROGNOSTIC FACTORS AND TREATMENT OUTCOMES IN 69 MAYO CLINIC PATIENTS

EHA Library, Erica Andres, 4160569

NUCLEOSIDE ANALOGUE-BASED INDUCTION (CLAG-M OR FLAGIDA) RESULTS IN HIGHER REMISSION RATES THAN STANDARD AML OR ALL-LIKE INTENSIVE INDUCTION REGIMENS IN MIXED PHENOTYPE ACUTE LEUKAEMIA. A STUDY FROM THE PETHEMA/PALG REGISTRIES.

EHA Library, Magdalena Karasek, 4160570

CONSTRUCTION OF A PROGNOSTIC MODEL FOR ACUTE MYELOID LEUKEMIA BASED ON FLOW CYTOMETRY IMMUNOPHENOTYPING USING MACHINE LEARNING METHODS.

EHA Library, Qing Ma, 4160571

OUTCOMES OF ADULT PATIENTS WITH NEWLY DIAGNOSED IDH-MUTATED ACUTE MYELOID LEUKEMIA RECEIVING INTENSIVE CHEMOTHERAPY PLUS VENETOCLAX

EHA Library, Jennifer Croden, 4160572

PROGNOSTIC VALUE OF IDH1 AND IDH2 MUTATIONS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA

EHA Library, Guillermo Ramil, 4160573

THE IMPACT OF ALLOGENIC STEM CELL TRANSPLANTATION ON NPM1MUTFLT3MUT AML PATIENTS IN FIRST REMISSION DEPENDS ON MRD STATUS AFTER CONSOLIDATION CHEMOTHERAPY: A RETROSPECTIVE MULTICENTRIC ITALIAN STUDY

EHA Library, Sara Consolo, 4160574

PROGNOSTIC SIGNIFICANCE OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA: IMPACT OF CONCURRENT GENETIC ALTERATIONS ON SURVIVAL

EHA Library, Hsin-Yu Lu, 4160575

A NOVEL RANDOM SURVIVAL FOREST MODEL FOR ADULT NPM1-MUTATED ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Yiyi Yao, 4160576

REVUMENIB ACTIVITY IN PATIENTS WITH ACUTE LEUKEMIA WITH NUP98R: RESULTS FROM THE AUGMENT-101 PHASE 1 STUDY

EHA Library, Ghayas Issa, 4160577

VENETOCLAX-AZACITIDINE PLUS IDARUBICIN IN OLDER AML PATIENTS: A PHASE II TRIAL EVALUATING FEASIBILITY AND EARLY OUTCOMES

EHA Library, Xinjie Chen, 4160578

COMPARABLE SURVIVAL OUTCOMES FOR SECONDARY AND DE NOVO ACUTE MYELOID LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Kehan Zhang, 4160579

IMPACT OF TYROSINE KINASE INHIBITORS ON OUTCOMES IN PHILADELPHIA CHROMOSOME-POSITIVE MIXED PHENOTYPE ACUTE LEUKEMIA: DATA FROM THE PETHEMA/PALG REGISTRY

EHA Library, Marta Sobas, 4160580

GENETIC ABNORMALITIES PREDICT OUTCOMES IN ACUTE MYELOID LEUKEMIA PATIENTS WITH CEBPA IN-FRAME MUTATIONS

EHA Library, Shunjie Yu, 4160581

NGS VS DIGITAL PCR FOR MRD MONITORING IN ACUTE MYELOID LEUKEMIA: A COMPARATIVE STUDY

EHA Library, Guillermo Ramil, 4160582

LONG TERM SURVIVAL AND VACCINE-INDUCED IMMUNE RESPONSES ARE COMPARABLE BETWEEN NPM1 MUTATED VS NPM1 WILD TYPE AML PATIENTS AFTER IMMUNOTHERAPY WITH VIDIDENCEL

EHA Library, Arjan van de Loosdrecht, 4160583

REAL-WORLD PATTERNS AND OUTCOMES IN AML PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: DATA FROM THE PETHEMA REGISTRY

EHA Library, Laura Torres Miñana, 4160584

PRELIMINARY RESULTS FROM RIVER-81, A PHASE 2 STUDY OF RVU120+VEN IN PATIENTS WITH AML FAILING FIRST LINE VEN+HMA

EHA Library, Noemi Angelosanto, 4160585

MITOXANTRONE HYDROCHLORIDE LIPOSOME-BASED INDUCTION REGIMENS FOR UNTREATED DE NOVO ACUTE MYELOID LEUKEMIA: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, MULTICOHORT STUDY

EHA Library, Shaowei Qiu, 4160586

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PARTIALLY OVERCOME THE ADVERSE PROGNOSTIC IMPACT OF TP53 ALTERATIONS IN AML PATIENTS.

EHA Library, Dan Feng, 4160587

EVALUATION OF THE 2022 ELN RISK CLASSIFICATION IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IDENTIFICATION OF A VERY POOR PROGNOSIS SUBGROUP

EHA Library, Huixian Wu, 4160588

COMPARING OUTCOMES OF PATIENTS WITH DE NOVO AND SECONDARY AML, TREATED FRONTLINE WITH VENETOCLAX AND HYPOMETHYLATING AGENTS: A MULTICENTER RETROSPECTIVE STUDY.

EHA Library, Ilaria Tanasi, 4160589

REAL WORLD OUTCOMES OF ADULT PATIENTS WITH NUP98 GENE REARRANGED ACUTE MYELOID LEUKEMIA

EHA Library, Laura Torres Miñana, 4160590

A PHASE I STUDY OF VENETOCLAX, AZACITIDINE, AND MITOXANTRONE HYDROCHLORIDE LIPOSOME IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Wenxiang Ren, 4160591

OUTCOMES OF THE ACUTE MYELOID LEUKEMIA-DEFINING MECOM REARRANGEMENT DIFFER BASED ON BLAST COUNT AT DIAGNOSIS

EHA Library, Wei-Ying Jen, 4160592

ENHANCED PROGNOSIS OF DMCEBPABZIP-INF MUTATIONS IN ACUTE MYELOID LEUKEMIA: INSIGHTS FROM A MULTI-CENTER CHINESE COHORT

EHA Library, Guanghui Chang, 4160593

PROGNOSTIC IMPACT OF EXTRAMEDULLARY DISEASE IN ACUTE MYELOID LEUKEMIA: A META-ANALYSIS

EHA Library, Yufan Lin, 4160594

COVALENT FLT3 INHIBITOR BMF-500 IN RELAPSED OR REFRACTORY (R/R) ACUTE LEUKEMIA (AL): PRELIMINARY PHASE 1 DATA FROM THE COVALENT-103 STUDY (NCT05918692)

EHA Library, Farhad Ravandi-Kashani, 4160595

TREATMENT AND SURVIVAL OF MIXED PHENOTYPE ACUTE LEUKAEMIA - A POPULATION-BASED COHORT

EHA Library, Lisa-Maj Christensen, 4160597

TREATMENT INTENSITY IS ASSOCIATED WITH DISTINCT LONGITUDINAL TRAJECTORIES OF FRAILTY IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Victoria Ling, 4160598

THE EFFICACY AND PROGNOSTIC EVALUATION OF BTG1 IN HYPOMETHYLATING AGENTS TREATMENT FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Shuai Su, 4160599

VENETOCLAX PLUS MITOXANTRONE HYDROCHLORIDE LIPOSOME AND AZACITIDINE AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Weiwei Qin, 4160600

TWICE WEEKLY LOW DOSE DECITABINE PLUS VENETOCLAX VERSUS AZACYTIDINE PLUS VENETOCLAX IN THE FRONTLINE TREATMENT OF ACUTE MYELOID LEUKEMIA, INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, Ciprian Tomuleasa, 4160601

CD4+ T CELLS, GRANZYME B+ NK, MZ B CELLS AND DIFFERENTIATED/SENESCENT CD4+CD28- T CELLS AFTER INDUCTION TREATMENT PREDICT AML PATIENT'S OUTCOME

EHA Library, Xin Huang, 4160602

THE RESULTS OF TREATMENT OF ACUTE LEUKEMIA DIAGNOSED DURING PREGNANCY

EHA Library, Vera Troitskaya, 4160603

SAFETY AND EFFICACY OF LOW-DOSE VENETOCLAX PLUS VORICONAZOLE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR INTENSIVE CHEMOTHERAPY

EHA Library, zhangbiao long, 4160604

PERI-TRANSPLANT KMT2A-REARRANGED MRD DYNAMICS AS A PROGNOSTIC MARKER IN ADULT ACUTE MYELOID LEUKEMIA

EHA Library, Lulu Wang, 4160605

FEASIBILITY AND SAFETY OF OUTPATIENT CONSOLIDATION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA

EHA Library, Laura Curras Sanchez, 4160606

EFFICACY AND SAFETY OF VAC (VENETOCLAX, AZACITIDINE, CHIDAMIDE) REINDUCTION TREATMENT FOR UNFIT ACUTE MYELOID LEUKEMIA PATIENTS FAILED TO RESPOND TO ONE CYCLE OF VA INDUCTION

EHA Library, Shengli Xue, 4160607

MEASURABLE MINIMAL RESIDUAL DISEASE BY AN ULTRA-SENSITIVE NGS METHOD TO EVALUATE THE RESPONSE IN ACUTE MYELOID LEUKEMIA, THE VENAQUI CLINICAL TRIAL

EHA Library, Rosa Maria Ayala Diaz, 4160608

TOWARDS THE USE OF ARTIFICIAL INTELLIGENCE MODELS IN THE ASSESSMENT OF ACUTE PROMYELOCYTIC LEUKEMIA - SYSTEMATIC REVIEW

EHA Library, Mihnea-Alexandru Găman, 4160609

VEN-BASED SCHEMES, ARE THEY BETTER THAN '3 + 7'?

EHA Library, Pedro Amorim Machado, 4160610

ALLOGENEIC TRANSPLANTATION VS. CHEMOTHERAPY AS CONSOLIDATION STRATEGIES IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS AFTER FIRST COMPLETE REMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Cilomar Martins de Oliveira Filho, 4160611

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH AML FROM 65 TO 74 YEARS UNFIT FOR FIRST-LINE INTENSIVE CHEMOTHERAPY IN JAPAN.

EHA Library, Fumiaki Fujii, 4160612

THE FUS::ERG FUSION IN ACUTE MYELOID LEUKEMIA: INSIGHTS INTO MOLECULAR PROFILES AND PROGNOSTIC IMPLICATIONS

EHA Library, Bingbing Han, 4160613

HEALTHCARE RESOURCE UTILIZATION IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX COMPARED TO HIGH- AND LOW-INTENSITY NON-VENETOCLAX THERAPIES

EHA Library, Pinkal Desai, 4160614

PROGNOSTIC IMPACT OF THE AML60+ SCORE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS

EHA Library, Tobias Silzle, 4160615

OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE IN REAL-WORLD BELGIAN CLINICAL PRACTICE

EHA Library, Adrien De Voeght, 4160616

SURVIVAL ANALYSIS OF LONG-TERM TREATMENT WITH VENETOCLAX-AZACITIDINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: MULTICENTRE REAL-WORLD OUTCOMES IN CHINA

EHA Library, Jing Zou, 4160617

CLINICAL EXPERIENCE WITH HDAC INHIBITOR-BASED PROTOCOLS IN MECOM-REARRANGED ACUTE MYELOID LEUKEMIA

EHA Library, Eitan Kugler, 4160618

REAL-LIFE STUDY ON GILTERITINIB RELATED INFECTIONS (GILTERINF): AN ITALIAN SEIFEM STUDY

EHA Library, Elisa Buzzatti, 4160619

OUTCOMES OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ACUTE MYELOID LEUKEMIA: THE THREE-SITE MAYO CLINIC CANCER CENTER EXPERIENCE.

EHA Library, Jabra Zarka, 4160620

VA COMBINED WITH LIPOSOMAL MITOXANTRONE: A NOVEL AND SAFE INDUCTION THERAPY FOR NEWLY DIAGNOSED AML

EHA Library, Yan Yu, 4160621

EFFECT OF OBESITY ON OVERALL SURVIVAL IN ELDERLY PATIENTS (>65 YEARS OLD) WITH ACUTE MYELOID LEUKEMIA - SINGLE-CENTER EXPERIENCE.

EHA Library, Karolina Bełdzińska, 4160622

RELATIONSHIP BETWEEN SALVAGE STRATEGIES AND OUTCOMES IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA AFTER FIRST-LINE INTENSIVE CHEMOTHERAPY

EHA Library, Lucas Lefèvre, 4160623

THE PREDICTIVE ROLE OF HEMATOLOGIC RECOVERY IN THE PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH AZACITIDINE-VENETOCLAX

EHA Library, Yan Li, 4160624

CLINICAL EFFICACY AND SAFETY OF VENETOCLAX COMBINED WITH HOMOHARRINGTONINE, AZACITIDINE, AND CYTARABINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Xin Yan, 4160625

IN-DEPTH IMMUNE AND METABOLIC PROFILING OF GAIA/CLL13 PATIENTS TO UNCOVER TREATMENT-SPECIFIC CHANGES TO THE T-CELL COMPARTMENT [CJ1]

EHA Library, Chaja F Jacobs, 4160626

GUT MICROBIOME IMBALANCE DRIVES IMMUNE EXHAUSTION VIA SHORT-CHAIN FATTY ACIDS IN CLL

EHA Library, Monika Szelest, 4160628

THE LANDSCAPE OF CLONAL HEMATOPOIESIS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Othman Al-Sawaf, 4160629

EGR2 MUTATIONS COOPERATE IN ACTIVATING NOTCH-1 PATHWAY AND LEAD TO BTK INHIBITORS RESISTANCE IN CLL

EHA Library, Alessia Morabito, 4160630

DIAGNOSTIC CRITERIA FOR NK-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA: VALIDATION THROUGH A MULTICENTRIC INTERNATIONAL STUDY

EHA Library, Thierry Lamy, 4160631

A CLINICAL-MOLECULAR MODEL FOR A PERSONALISED PREDICTION OF TIME TO FIRST TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

EHA Library, Aleix Real, 4160632

UNVEILING STAT3-DRIVEN CIRCULAR RNAS ALTERATIONS IN T-LARGE GRANULAR LYMPHOCYTE LEUKEMIA (T-LGLL)

EHA Library, Elisa Rampazzo, 4160633

CONTROLLED PERFUSION OF A VASCULARIZED SCAFFOLD WITHIN A 3D PRINTED BIOREACTOR TO STUDY CLL CELLS TRAFFICKING

EHA Library, Riccardo Pinos, 4160634

IMPACT OF TUMOR BURDEN AND PRIOR VENETOCLAX TREATMENT ON MOSUNETUZUMAB-MEDIATED TUMOR CONTROL IN RELAPSED/REFRACTORY CLL

EHA Library, Hyun Yong Jin, 4160635

GENOMIC CHARACTERIZATION OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ALTERATIONS FROM A SPANISH REAL-WORLD COHORT TREATED WITH TARGETED AGENTS

EHA Library, Joanna Kamaso, 4160636

UNCOVERING A CRITICAL ROLE FOR VAV1 IN α4ß1-BCR CROSSTALK IN CHRONIC LYMPHOCYTIC LEUKAEMIA: NOVEL INSIGHTS INTO DISEASE MECHANISMS

EHA Library, Tahera Alnassfan, 4160637

VENETOCLAX-ACALABRUTINIB FOR CLL PATIENTS RELAPSING AFTER VENETOCLAX-ANTICD20 TREATMENT: HIGHLY EFFECTIVE AND LOW TOXICITY. INTERIM ANALYSIS OF HOVON 159/REVEAL PHASE 2 TRIAL

EHA Library, Sabina Kersting, 4160638

ALLOGENEIC STEM CELL TRANSPLANTATION IS EFFECTIVE AFTER PATHWAY INHIBITOR TREATMENTS IN CLL; A RETROSPECTIVE STUDY ON BEHALF OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT

EHA Library, Michel van Gelder, 4160639

SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

EHA Library, Mazyar Shadman, 4160640

COMBINATION OF ZANUBRUTINIB + VENETOCLAX FOR TREATMENT-NAIVE CLL/SLL: RESULTS IN SEQUOIA ARM D

EHA Library, Mazyar Shadman, 4160641

MRD GUIDED MESUTOCLAX PLUS ORELABRUTINIB FOR CLL/SLL DEMONSTRATES HIGH RESPONSE AND EARLY MRD CLEARANCE WITH GOOD TOLERABILITY: PRELIMINARY ANALYSIS FROM AN ONGOING PHASE II DOSE OPTIMIZATION STUDY

EHA Library, Yang Liang, 4160642

USING MINIMAL RESIDUAL DISEASE STATUS TO GUIDE VENETOCLAX TREATMENT DURATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: INTERIM RESULTS FROM THE PHASE II VENETOSTOP STUDY

EHA Library, Leora Boussi, 4160643

A PHASE 1 STUDY OF SGR-1505, AN ORAL, POTENT MALT1 INHIBITOR FOR RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

EHA Library, Stephen Spurgeon, 4160644

10-YEAR FOLLOW-UP OF A RANDOMIZED PHASE-2 STUDY OF IBRUTINIB OR IBRUTINIB PLUS RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Jan Burger, 4160645

SERIOUS INFECTIONS IN PATIENTS WITH CLL/SLL TREATED WITH COMBINATION VENETOCLAX AND OBINUTUZUMAB COMPARED WITH THOSE TREATED WITH ZANUBRUTINIB: A REAL-WORLD STUDY

EHA Library, Nicole Lamanna, 4160646

REAL-WORLD COMPARATIVE EFFECTIVENESS OF VENETOCLAX-OBINUTUZUMAB VERSUS SECOND-GENERATION BRUTON TYROSINE KINASE INHIBITORS IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Beenish Manzoor, 4160647

TREATMENT EFFECTIVENESS IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING VENETOCLAX-BASED THERAPY AFTER PROGRESSION ON A COVALENT BRUTON TYROSINE KINASE INHIBITOR (CBTKI)

EHA Library, Beenish Manzoor, 4160648

ANALYSIS OF COVID-19 INFECTIONS WITH FIXED-DURATION ACALABRUTINIB-VENETOCLAX COMBINATIONS IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA IN THE PHASE 3 AMPLIFY TRIAL

EHA Library, Jennifer Brown, 4160649

PHASE 1 STUDY OF FCN-338, A NOVEL BCL-2 INHIBITOR IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY

EHA Library, Huiqiang Huang, 4160650

IMPACT OF IBRUTINIB ON QUALITY OF LIFE IN PATIENTS WITH EARLY-STAGE, ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE PHASE III CLL12 TRIAL - MATCHING SAFETY TO PATIENT-REPORTED OUTCOMES

EHA Library, Ellinor Goergen, 4160651

DEVELOPMENT OF A CLINICAL MACHINE LEARNING TOOL FOR THE PREDICTION OF AUTOIMMUNE HEMOLYTIC ANEMIA IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION BASED MULTILAYER PERCEPTRON MODEL

EHA Library, Rayan Ramadan, 4160652

REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIRST-LINE BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Ryan Jacobs, 4160653

FIRST WORLDWIDE REAL-LIFE DATA ON FIXED-DURATION IBRUTINIB+VENETOCLAX TREATMENT FOR PREVIOUSLY UNTREATED CLL/SLL PATIENTS: INITIAL INTERIM ANALYSIS OF SPAIN´S LI+VE OBSERVATIONAL STUDY

EHA Library, JOSE ANGEL HERNANDEZ RIVAS, 4160654

FIXED-DURATION BTKI-VENETOCLAX COMBINATIONS IN CLL: AN INDIRECT COMPARISON OF AMPLIFY AND CAPTIVATE TRIALS

EHA Library, stefano molica, 4160655

COMPARATIVE EFFICACY OF ZANUBRUTINIB VERSUS FIXED-DURATION ACALABRUTINIB PLUS VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Talha Munir, 4160656

GENOTYPING OF SLC22A4 SNP RS460089 IN A REAL-LIFE CML COHORT: IMPLICATIONS FOR IMATINIB RESPONSE AND STABLE DMR ACHIEVEMENT

EHA Library, Katerina Machova, 4160657

OVERCOMING ASCIMINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA WITH IDENTIFICATION OF THERAPEUTIC STRATEGIES TARGETING BCR::ABL1 MUTATIONS

EHA Library, Seiichi Okabe, 4160658

LOW SERUM IL-8 MAY CONTRIBUTES TO TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Yuki Fujioka, 4160659

GERMLINE VARIANTS IN PEDIATRIC CHRONIC MYELOID LEUKEMIA

EHA Library, Tabita Ghete, 4160660

EARLY PREDICTION OF MR4.5 ATTAINMENT AND SUSTAINED RESPONSE IN CHRONIC MYELOID LEUKEMIA TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS: ANALYSIS FROM THE JALSG CML212 ROAD TO MR4.5 STUDY

EHA Library, TAKAAKI ONO, 4160661

PROSPECTIVE VALIDATION OF A DNA/RNA MRD-BASED RISK STRATIFICATION MODEL DURING TWO-PHASE TKI DOSE DE-ESCALATION FOR DISCONTINUATION IN CML

EHA Library, Katerina Machova, 4160662

IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH ASCIMINIB (ASC) VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS (IS-TKIS) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML): ASC4FIRST WK 48 ANALYSIS

EHA Library, Andreas Hochhaus, 4160663

RESULTS FROM THE FIRST-IN-CHILD PHASE II TRIAL (ITCC-054/COG-AAML1921) OF BOSUTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED (ND) CHRONIC MYELOID LEUKEMIA (CML).

EHA Library, Kim Schellekens, 4160664

ASSESSMENT OF TRANSITIONING FROM HIGH-POTENCY TO LOW-POTENCY INHIBITORS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: THE DOWNGRADING-IMPACT (D-IMPACT) PROJECT, A CML CAMPUS STUDY

EHA Library, Simona Bernardi, 4160665

THE FRONTLINE SECOND GENERATION TYROSINE KINASE INHIBITORS BRING TREATMENT-FREE REMISSION TO MORE PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Naoto Takahashi, 4160666

MYELOPROLIFERATIVE NEOPLASMS WITH CONCOMITANT CHRONIC MYELOID LEUKAEMIA ARE ASSOCIATED WITH TKI RESISTANCE AND POOR OUTCOMES: A REVIEW OF 46 CASES

EHA Library, Laura Li Gagnon, 4160667

ASC4OPT STUDY: HIGH EFFICACY AND FAVORABLE TOLERABILITY OF ASCIMINIB ONCE OR TWICE DAILY IN CML PATIENTS WITH SUBOPTIMAL RESPONSE, RESISTANCE OR INTOLERANCE OF 2 OR MORE TYROSINE KINASE INHIBITORS

EHA Library, Andreas Hochhaus, 4160668

UPDATED RESULTS OF MANAGED-ACCESS PROGRAM (MAP) OF ASCIMINIB USE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN 3 CLINICAL CENTERS.

EHA Library, Ekaterina Chelysheva, 4160669